GAD1 and type 1 diabetes mellitus: In a recent intervention trial, Ludvigsson et al. treated new-onset (<18 mo) T1D children positive for anti-GAD aAbs with two subcutaneous injections of GAD (20 μg) or placebo in alum adjuvant and followed this children for 30 months.